Cargando…

Treatment Patterns and Pharmacoutilization in Patients Affected by Psoriasis: An Observational Study in an Italian Real-World Setting

BACKGROUND: Real-world data can inform the use of biologics for psoriasis (PSO). OBJECTIVE: The aim was to evaluate treatment patterns and analyze pharmacoutilization in PSO patients in a real-world Italian setting, with a focus on the biologics most recently introduced. METHODS: An observational st...

Descripción completa

Detalles Bibliográficos
Autores principales: Perrone, Valentina, Losi, Serena, Maiorino, Alessia, Antonelli, Silvia, Giovannitti, Massimo, Giacomini, Elisa, Sangiorgi, Diego, Degli Esposti, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114260/
https://www.ncbi.nlm.nih.gov/pubmed/35041194
http://dx.doi.org/10.1007/s40801-021-00290-3
_version_ 1784709733854216192
author Perrone, Valentina
Losi, Serena
Maiorino, Alessia
Antonelli, Silvia
Giovannitti, Massimo
Giacomini, Elisa
Sangiorgi, Diego
Degli Esposti, Luca
author_facet Perrone, Valentina
Losi, Serena
Maiorino, Alessia
Antonelli, Silvia
Giovannitti, Massimo
Giacomini, Elisa
Sangiorgi, Diego
Degli Esposti, Luca
author_sort Perrone, Valentina
collection PubMed
description BACKGROUND: Real-world data can inform the use of biologics for psoriasis (PSO). OBJECTIVE: The aim was to evaluate treatment patterns and analyze pharmacoutilization in PSO patients in a real-world Italian setting, with a focus on the biologics most recently introduced. METHODS: An observational study based on administrative databases was conducted. Patients were included based on PSO diagnosis identified by either discharge diagnosis or exemption code or prescription of anti-psoriatic topical drugs (proxy of diagnosis). To describe patient characteristics and treatment patterns using the most up-to-date data, two different approaches were used: a cross-sectional study performed during 2016–2018, and a longitudinal study conducted with patients who received their first biological/targeted synthetic drugs (naïve patients) in 2014 and 2017 (the inclusion periods). RESULTS: During 2016–2018, the number of prevalent patients diagnosed with PSO was 194,054 (2016), 210,830 (2017), and 225,171 (2018). The percentage of patients receiving biologics or targeted synthetic agents ranged from 1.5 to 2.1%. Among them, naïve patients receiving interleukin (IL) inhibitors increased from 37.5% (2016) to 69.4% (2018), while those receiving anti-tumor necrosis factor (anti-TNF) decreased from 62.5% (2016) to 30.6% (2018). The longitudinal analysis included 894 and 1218 naïve patients in 2014 and 2017, respectively, of whom 7.2% (2014) and 6.9% (2017) switched therapy after a mean of 7.1 (2014) and 6.9 (2017) months. Overall, 259 patients were prescribed ixekizumab starting in 2017, of whom 73% were naïve. Ixekizumab was prescribed as monotherapy to 52.5%. CONCLUSIONS: The proportion of patients receiving biologics appeared constant over the years, with an increasing number of naïve patients being prescribed IL-17 inhibitors. Ixekizumab patients were mostly naïve.
format Online
Article
Text
id pubmed-9114260
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-91142602022-05-19 Treatment Patterns and Pharmacoutilization in Patients Affected by Psoriasis: An Observational Study in an Italian Real-World Setting Perrone, Valentina Losi, Serena Maiorino, Alessia Antonelli, Silvia Giovannitti, Massimo Giacomini, Elisa Sangiorgi, Diego Degli Esposti, Luca Drugs Real World Outcomes Original Research Article BACKGROUND: Real-world data can inform the use of biologics for psoriasis (PSO). OBJECTIVE: The aim was to evaluate treatment patterns and analyze pharmacoutilization in PSO patients in a real-world Italian setting, with a focus on the biologics most recently introduced. METHODS: An observational study based on administrative databases was conducted. Patients were included based on PSO diagnosis identified by either discharge diagnosis or exemption code or prescription of anti-psoriatic topical drugs (proxy of diagnosis). To describe patient characteristics and treatment patterns using the most up-to-date data, two different approaches were used: a cross-sectional study performed during 2016–2018, and a longitudinal study conducted with patients who received their first biological/targeted synthetic drugs (naïve patients) in 2014 and 2017 (the inclusion periods). RESULTS: During 2016–2018, the number of prevalent patients diagnosed with PSO was 194,054 (2016), 210,830 (2017), and 225,171 (2018). The percentage of patients receiving biologics or targeted synthetic agents ranged from 1.5 to 2.1%. Among them, naïve patients receiving interleukin (IL) inhibitors increased from 37.5% (2016) to 69.4% (2018), while those receiving anti-tumor necrosis factor (anti-TNF) decreased from 62.5% (2016) to 30.6% (2018). The longitudinal analysis included 894 and 1218 naïve patients in 2014 and 2017, respectively, of whom 7.2% (2014) and 6.9% (2017) switched therapy after a mean of 7.1 (2014) and 6.9 (2017) months. Overall, 259 patients were prescribed ixekizumab starting in 2017, of whom 73% were naïve. Ixekizumab was prescribed as monotherapy to 52.5%. CONCLUSIONS: The proportion of patients receiving biologics appeared constant over the years, with an increasing number of naïve patients being prescribed IL-17 inhibitors. Ixekizumab patients were mostly naïve. Springer International Publishing 2022-01-18 /pmc/articles/PMC9114260/ /pubmed/35041194 http://dx.doi.org/10.1007/s40801-021-00290-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research Article
Perrone, Valentina
Losi, Serena
Maiorino, Alessia
Antonelli, Silvia
Giovannitti, Massimo
Giacomini, Elisa
Sangiorgi, Diego
Degli Esposti, Luca
Treatment Patterns and Pharmacoutilization in Patients Affected by Psoriasis: An Observational Study in an Italian Real-World Setting
title Treatment Patterns and Pharmacoutilization in Patients Affected by Psoriasis: An Observational Study in an Italian Real-World Setting
title_full Treatment Patterns and Pharmacoutilization in Patients Affected by Psoriasis: An Observational Study in an Italian Real-World Setting
title_fullStr Treatment Patterns and Pharmacoutilization in Patients Affected by Psoriasis: An Observational Study in an Italian Real-World Setting
title_full_unstemmed Treatment Patterns and Pharmacoutilization in Patients Affected by Psoriasis: An Observational Study in an Italian Real-World Setting
title_short Treatment Patterns and Pharmacoutilization in Patients Affected by Psoriasis: An Observational Study in an Italian Real-World Setting
title_sort treatment patterns and pharmacoutilization in patients affected by psoriasis: an observational study in an italian real-world setting
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114260/
https://www.ncbi.nlm.nih.gov/pubmed/35041194
http://dx.doi.org/10.1007/s40801-021-00290-3
work_keys_str_mv AT perronevalentina treatmentpatternsandpharmacoutilizationinpatientsaffectedbypsoriasisanobservationalstudyinanitalianrealworldsetting
AT losiserena treatmentpatternsandpharmacoutilizationinpatientsaffectedbypsoriasisanobservationalstudyinanitalianrealworldsetting
AT maiorinoalessia treatmentpatternsandpharmacoutilizationinpatientsaffectedbypsoriasisanobservationalstudyinanitalianrealworldsetting
AT antonellisilvia treatmentpatternsandpharmacoutilizationinpatientsaffectedbypsoriasisanobservationalstudyinanitalianrealworldsetting
AT giovannittimassimo treatmentpatternsandpharmacoutilizationinpatientsaffectedbypsoriasisanobservationalstudyinanitalianrealworldsetting
AT giacominielisa treatmentpatternsandpharmacoutilizationinpatientsaffectedbypsoriasisanobservationalstudyinanitalianrealworldsetting
AT sangiorgidiego treatmentpatternsandpharmacoutilizationinpatientsaffectedbypsoriasisanobservationalstudyinanitalianrealworldsetting
AT degliespostiluca treatmentpatternsandpharmacoutilizationinpatientsaffectedbypsoriasisanobservationalstudyinanitalianrealworldsetting